Significance of medication history at the time of entry into the COPDGene study: Relationship with exacerbation and CT metrics

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 12, Issue 4, 2015, Pages 366-373

  Park, Seoung Ju ^a,b   Make, Barry ^a   Hersh, Craig P ^c   Bowler, Russell P ^a  

^a DEPARTMENT OF MEDICINE   (United States)

^b Chonbuk National University Medical School and Hospital   (South Korea)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

CT metrics; exacerbation; medication; triple therapy

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; MUSCARINIC RECEPTOR BLOCKING AGENT; BRONCHODILATING AGENT;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; EMPHYSEMA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SMOKING; THICKNESS; TREATMENT INDICATION; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIAGNOSTIC IMAGING; DISEASE COURSE; GENETICS; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; VERY ELDERLY; X-RAY COMPUTED TOMOGRAPHY;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; AGED, 80 AND OVER; BRONCHODILATOR AGENTS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUSCARINIC ANTAGONISTS; PHENOTYPE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84939452385     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2014.948999     Document Type: Article

References (25)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop summary [updated 2013]. Available from: http://www.goldcopd.org/ (accessed September 6, 2013
2. Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T, Marciniuk DD, Denberg T, Schúnemann H, Wedzicha W, MacDonald R, Shekelle P. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011; 155: 179-191
3. Bourbeau J, Sebaldt RJ, Day A, Bouchard J, Kaplan A, Hernandez P, Rouleau M, Petrie A, Foster G, Thabane L, Haddon J, Scaler A. Practice patterns in the management of chronic obstructive pulmonary disease in primary practice: the CAGE study. Can Respir J 2008; 15: 13-19
4. Hernandez P, Balter MS, Bourbeau J, Chan CL, Marciniuk DD, Walker ST. Canadian practice assessment in chronic obstructive pulmonary disease: respiratory specialist physician perception versus patient reality. Can Respir J 2013; 20: 97-105
5. Seaman J, Leonard AC, Panos RJ. Health care utilization history, GOLD guidelines, and respiratory medication prescriptions in patients with COPD. Int J Chron Obstruct Pulmon Dis 2010; 5: 89-97
6. Solem CT, Lee TA, Joo MJ, Lambert BL, Walton SM, Pickard AS. Complexity of medication use in newly diagnosed chronic obstructive pulmonary disease patients. Am J Geriatr Pharmacother 2012; 10: 110-122
7. Matsuoka S, Yamashiro T, Washko GR, Kurihara Y, Nakajima Y, Hatabu H. Quantitative CT assessment of chronic obstructive pulmonary disease. Radiographics 2010; 30: 55-66
8. Han MK, Kazerooni EA, Lynch DA, Liu LX, Murray S, Curtis JL, Criner GJ, Kim V, Bowler RP, Hanania NA, Anzueto AR, Make BJ, Hokanson JE, Crapo JD, Silverman EK, Martinez FJ, Washko GR., COPDGene Investigators. Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology 2011; 261: 274-282
9. Regan EA, Hokanson JE, Murphy JR, Make B, Lynch DA, Beaty TH, Curran-Everett D, Silverman EK, Crapo JD. Genetic epidemiology of COPD (COPDGene) study design. COPD 2010; 7: 32-43
10. Han MK, Muellerova H, Curran-Everett D, Dransfield MT, Washko GR, Regan EA, Bowler RP, Beaty TH, Hokanson JE, Lynch DA, Jones PW, Anzueto A, Martinez FJ, Crapo JD, Silverman EK, Make BJ. GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med 2013; 1: 43-50
11. Ferris BG. Epidemiology Standardization Project (American Thoracic Society). Am Rev Respir Dis 1978; 118: 1-120
12. COPDGene CT Workshop Group, Barr RG, Berkowitz EA, Bigazzi F, Bode F, Bon J, Bowler RP, Chiles C, Crapo JD, Criner GJ, Curtis JL, Dass C, Dirksen A, Dransfield MT, Edula G, Erikkson L, Friedlander A, Galperin-Aizenberg M, Gefter WB, Gierada DS, Grenier PA, Goldin J, Han MK, Hanania NA, Hansel NN, Jacobson FL, Kauczor HU, Kinnula VL, Lipson DA, Lynch DA, MacNee W, Make BJ, Marnary AJ, Mann H, Marchetti N, Mascalchi M, McLennan G, Murphy JR, Naidich D, Nath H, Newell JD. Jr, Pistolesi M, Regan EA, Reilly JJ, Sandhaus R, Schroeder JD, Sciurba F, Shaker S, Sharafkhaneh A, Silverman EK, Steiner RM, Strange C, Sverzellati N, Tashian JH, van Beek EJ, Washington L, Washko GR, Westney G, Wood SA, Woodruff PG A combined pulmonary-radiology workshop for visual evaluation of COPD: study design, chest CT findings and concordance with quantitative evaluation. COPD 2012; 9: 151-159
13. Restrepo RD, Alvarez MT, Wittnebel LD, Sorenson H, Wettstein R, Vines DL, Sikkema-Ortiz J, Gardner DD, Wilkins RL. Medication adherence issues in patients treated for COPD. Int J Chron Obstruct Pulmon Dis 2008; 3: 371-384
14. Marton JP, Boulanger L, Friedman M, Dixon D, Wilson J, Menzin J. Assessing the costs of chronic obstructive pulmonary disease: the state Medicaid perspective. Respir Med 2006; 100: 996-1005
15. Welte T, Miravitlles M, Hernandez P, Eriksson G, Peterson S, Polanowski T, Kessler R. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 741-750
16. Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, Bishop G, Anthony J, Cowie R, Field S, Hirsch A, Hernandez P, Rivington R, Road J, Hoffstein V, Hodder R, Marciniuk D, McCormack D, Fox G, Cox G, Prins HB, Ford G, Bleskie D, Doucette S, Mayers I, Chapman K, Zamel N, FitzGerald M., Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007; 146: 545-555
17. Cazzola M, Andó F, Santus P, Ruggeri P., Di Marco F, Sanduzzi A, D'Amato M A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-To-very severe COPD. Pulm Pharmacol Ther 2007; 20: 556-561
18. Singh D, Brooks J, Hagan G, Cahn A, O'Connor BJ. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008; 63: 592-598
19. Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res 2013; 5: 235-245
20. Lee TA, Wilke C, Joo M, Stroupe KT, Krishnan JA, Schumock GT, Pickard AS. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease. Arch Intern Med 2009; 169: 1403-1410
21. Jenkins CR, Celli B, Anderson JA, Ferguson GT, Jones PW, Vestbo J, Yates JC, Calverly PM. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. Eur Respir J 2012; 39: 38-45
22. Martinez CH, Chen YH, Westgate PM, Liu LX, Murray S, Curtis JL, Make BJ, Kazerooni EA, Lynch DA, Marchetti N, Washko GR, Martinez FJ, Han MK., COPDGene Investigators. Relationship between quantitative CT metrics and health status and BODE in chronic obstructive pulmonary disease. Thorax 2012; 67: 399-406
23. Yu AP, Guérin A, de Leon DP, Ramakrishnan K, Wu EQ, Mocarski M, Blum SI, Setyawan J. Clinical and economic outcomes of multiple versus single long-Acting inhalers in COPD. Respir Med 2011; 105: 1861-1871
24. Yu AP, Guérin A, de Leon DP, Ramakrishnan K, Wu EQ, Mocarski M, Blum S, Setyawan J. Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-Acting maintenance inhalers. J Med Econ 2011; 14: 486-496
25. Wan ES, DeMeo DL, Hersh CP, Shapiro SD, Rosiello RA, Sama SR, Fuhlbrigge AL, Foreman MG, Silverman EK. Clinical predictors of frequent exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). Respir Med 2011; 105: 588-594